Ronald S Go1,2, Mohammed Al-Hamadani3,4, Nilay D Shah2,5, Cynthia S Crowson5, Sara J Holton6, Elizabeth B Habermann2,5,7. 1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota. 3. Department of Medical Research, Gundersen Medical Foundation, La Crosse, Wisconsin. 4. Department of Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 6. Mayo Clinic Cancer Registry, Rochester, Minnesota. 7. Division of Surgery, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Prior studies have shown that a higher hospital volume or physician caseload is associated with better outcomes for complex and uncommon surgical procedures. Similar studies in the medical management of rare diseases such as hematologic cancers are limited. This retrospective, observational study using the US National Cancer Data Base determined the extent to which the number of new non-Hodgkin lymphoma (NHL) patients treated annually at a treatment facility affected overall survival (OS). METHODS: There were 278,985 patients treated at 1151 facilities from 1998 to 2006. Treatment facilities were classified by quartiles based on the average number of new NHL patients seen annually: quartile 1 (Q1), 2 to 13 patients; quartile 2 (Q2), 14 to 20 patients; quartile 3 (Q3), 21 to 32 patients; and quartile 4 (Q4), 33 or more patients. The outcome of interest was OS according to facility volume. RESULTS: The unadjusted median OS was 61.8 months for Q1, 65.9 months for Q2, 71.4 months for Q3, and 83.6 months for Q4. A multivariate analysis that was adjusted for demographic (sex, age, race, and ethnicity), socioeconomic (income and insurance type), geographic (area of residence), disease-specific (NHL subtype and stage), and facility-specific factors (type and location) showed that the facility volume was associated with OS. Compared with patients at Q4 facilities, patients at lower quartile facilities had higher mortality (hazard ratio for Q3, 1.05 [95% confidence interval, 1.04-1.06]; hazard ratio for Q2, 1.08 [95% confidence interval, 1.07-1.10]; hazard ratio for Q1, 1.14 [95% confidence interval, 1.11-1.17]). CONCLUSIONS: NHL patients treated at higher volume facilities may survive longer than those treated at lower volume facilities. Further work is needed to understand the mechanisms of these differences and whether volume should be considered in the determination of referrals for NHL patients. Cancer 2016;122:2552-9.
BACKGROUND: Prior studies have shown that a higher hospital volume or physician caseload is associated with better outcomes for complex and uncommon surgical procedures. Similar studies in the medical management of rare diseases such as hematologic cancers are limited. This retrospective, observational study using the US National Cancer Data Base determined the extent to which the number of new non-Hodgkin lymphoma (NHL) patients treated annually at a treatment facility affected overall survival (OS). METHODS: There were 278,985 patients treated at 1151 facilities from 1998 to 2006. Treatment facilities were classified by quartiles based on the average number of new NHLpatients seen annually: quartile 1 (Q1), 2 to 13 patients; quartile 2 (Q2), 14 to 20 patients; quartile 3 (Q3), 21 to 32 patients; and quartile 4 (Q4), 33 or more patients. The outcome of interest was OS according to facility volume. RESULTS: The unadjusted median OS was 61.8 months for Q1, 65.9 months for Q2, 71.4 months for Q3, and 83.6 months for Q4. A multivariate analysis that was adjusted for demographic (sex, age, race, and ethnicity), socioeconomic (income and insurance type), geographic (area of residence), disease-specific (NHL subtype and stage), and facility-specific factors (type and location) showed that the facility volume was associated with OS. Compared with patients at Q4 facilities, patients at lower quartile facilities had higher mortality (hazard ratio for Q3, 1.05 [95% confidence interval, 1.04-1.06]; hazard ratio for Q2, 1.08 [95% confidence interval, 1.07-1.10]; hazard ratio for Q1, 1.14 [95% confidence interval, 1.11-1.17]). CONCLUSIONS:NHLpatients treated at higher volume facilities may survive longer than those treated at lower volume facilities. Further work is needed to understand the mechanisms of these differences and whether volume should be considered in the determination of referrals for NHLpatients. Cancer 2016;122:2552-9.
Authors: Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff Journal: Cancer Date: 2018-09-14 Impact factor: 6.860
Authors: Julie Hallet; Nicole J Look Hong; Victoria Zuk; Laura E Davis; Vaibhav Gupta; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: Gastric Cancer Date: 2019-12-13 Impact factor: 7.370
Authors: Julie Hallet; Laura E Davis; Alyson L Mahar; Ying Liu; Victoria Zuk; Vaibhav Gupta; Craig C Earle; Natalie G Coburn Journal: Gastric Cancer Date: 2019-10-18 Impact factor: 7.370
Authors: Jordan R Pollock; M Lane Moore; Jacob S Hogan; Jack M Haglin; Joseph C Brinkman; Matthew K Doan; Anikar Chhabra Journal: Arthrosc Sports Med Rehabil Date: 2021-11-04